{"id":"f573-for-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, F573 for injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"F573 for injection is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:26.395Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05689645","phase":"PHASE2","title":"F573 for Injection for the Treatment of Liver Injury/Failure","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2023-03-24","conditions":"Acute Liver Failure, Acute-On-Chronic Liver Failure","enrollment":97},{"nctId":"NCT04820049","phase":"PHASE1","title":"F573 Ia Clinical Trial","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2021-02-08","conditions":"Tolerance, Pharmacokinetic","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"F573 for injection","genericName":"F573 for injection","companyName":"Beijing Continent Pharmaceutical Co, Ltd.","companyId":"beijing-continent-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"F573 for injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}